| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-144SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF2519-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-145SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-54790SS | |||
| Azide and BSA Free | NBP2-80644 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-59724SS | |||
| Azide and BSA Free | NBP2-80643 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1955-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB2519-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB25191-SP | |||
| Carrier Free | FAB25191V-100UG | |||
| Carrier Free | FAB25191U-100UG | |||
| Carrier Free | FAB25191T-100UG | |||
| Carrier Free | FAB25191S-100UG | |||
| Carrier Free | FAB25191R-100UG | |||
| Carrier Free | FAB25191N-100UG | |||
| Carrier Free | FAB25191G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | MAB19553-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB19552-SP | |||
![Immunohistochemistry: CD36 Antibody [NB400-144] - Timp4-deficiency results in defective lipid digestion and absorption. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed and HFD-fed WT and Timp4-/- mice. Western blot (C) and mRNA (D) for CD36 in enterocyte fraction of chow-fed and HFD-fed WT and Timp4-/- mice (collected from the proximal small intestine). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Immunohistochemistry-NB400-144-img0016.jpg "<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Immunohistochemistry: CD36 Antibody [NB400-144] - Timp4-deficiency results in defective lipid digestion and absorption. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed and HFD-fed WT and Timp4-/- mice. Western blot (C) and mRNA (D) for CD36 in enterocyte fraction of chow-fed and HFD-fed WT and Timp4-/- mice (collected from the proximal small intestine). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license.")
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: CD36 Antibody [NB400-144] - Total protein from Human Skin and Adipose tissue, Mouse Adipose and Rat Adipose tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-CD36 in 5% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0009.jpg)
![Immunohistochemistry-Paraffin: CD36 Antibody [NB400-144] - Staining of CD36 in human adipocytes.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Immunohistochemistry-Paraffin-NB400-144-img0005.jpg)
![Western Blot: CD36 Antibody [NB400-144] - Mouse primary muscle cell lysate. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CD36 Antibody [NB400-144] - Bone marrrow derived mouse macrophages stained with CD36 antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Immunocytochemistry-Immunofluorescence-NB400-144-img0017.jpg)
![Western Blot: CD36 Antibody [NB400-144] - Detection of CD36 in human adipocyte extract (30 ug). Lane 1: 0.5 ug/ml NB 400-144; lane 2: 2 ug/ml NB 400-144. ECL: 3 second exposure.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0004.jpg)
![Western Blot: Rabbit Polyclonal CD36 Antibody [NB400-144] - The western blot was conducted on avian (passerine) skeletal muscle tissue homogenate. 6ug of total protein was loaded and GAPDH was probed to ensure total protein loads were similar across samples. Rabbit polyclonal CD36 antibody (NB400-144) was used at 1:5000 dilution (diluted in 5% milk). CD36 and GAPDH were probed sequentially - not multiplexed. CD36 produced a band above 40kDa and GAPDH at 36kDa. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb400-144_rabbit-polyclonal-cd36-antibody-western-blot-13202413439..png)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-144] - Timp4-deficiency results in defective lipid digestion & absorption. Fecal triglyceride (TG) content (Ai) in chow- or HFD-fed WT & Timp4−/− mice. Fecal lipid analysis by thin layer chromatography in chow-fed (Aii) & HFD-fed (iii) WT & Timp4−/− mice. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed & HFD-fed WT & Timp4−/− mice. Western blot (C) & mRNA (D) levels for CD36 in enterocyte fraction of chow-fed & HFD-fed WT & Timp4−/− mice (collected from the proximal small intestine). (E) Triglyceride levels in enterocytes collected from the proximal small intestine. Averaged data are presented as mean ± S.E.M & analyzed by ANOVA. * indicates significance (p < 0.05). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202415293346.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - Timp4-deficiency results in defective lipid digestion & absorption. Fecal triglyceride (TG) content (Ai) in chow- or HFD-fed WT & Timp4−/− mice. Fecal lipid analysis by thin layer chromatography in chow-fed (Aii) & HFD-fed (iii) WT & Timp4−/− mice. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed & HFD-fed WT & Timp4−/− mice. Western blot (C) & mRNA (D) levels for CD36 in enterocyte fraction of chow-fed & HFD-fed WT & Timp4−/− mice (collected from the proximal small intestine). (E) Triglyceride levels in enterocytes collected from the proximal small intestine. Averaged data are presented as mean ± S.E.M & analyzed by ANOVA. * indicates significance (p < 0.05). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241535667.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - MiR-29a inhibits the expression of fatty acid translocase CD36 by targeting 3’ untranslated region (UTR). (A) qPCR analysis of Cd36 in live tissue. (B) Representative immunoblotting bands & densitometric results of CD36 in liver tissue. (C) qPCR analysis of cd36 expression of HepG2 cells in vitro after 48h transfection of scramble sequence or miR-29a-mimic. Data obtained from six independent experiments. (D) Upper panel, sequence information, & mutual pairing status of CD36-3’UTR, mmu-miR29a, & CD36-3’UTR Mut. Note that red characters represent mismatching sites. HepG2 was first transfected with CD36-3’UTR or CD36-3’UTR mutant luciferase reporter construct then treated with control medium (ctrl), miRNA-scramble, or miR-29a mimic, & finally lysed to detect the luciferase signal. Data are expressed as mean ± SE. * p < 0.05, ** p < 0.01, & *** p < 0.001 between the indicated groups. WT, wild type mice. HFD, high-fat diet. miR-29a, mice harboring overexpression of miR-29a. mmu-miR29a, mouse-origin miR-29a. ctrl, control. Mut, mutant. UTR, untranslated region. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31652636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202416173544.jpg)
![Immunohistochemistry: CD36 Antibody - BSA Free [NB400-144] - Integrin beta 3 modulates SMC transdifferentiation. a–c Mice were fed a HFD for 6 or 16 weeks as indicated, & then transverse aortic root sections were stained. In a, b sections from ApoE(−/−), SMMHC-CreERT2, ROSA26R(mTmG/+) mice were stained for SMA, GFP (fate marker), nuclei (DAPI), & either integrin beta 3 (a) or CD36 (b). Dashed yellow lines separate cap from core (a, b) & core from media (b). n = 5. In c sections from ApoE(−/−) mice that were also wild type or null for Itgb3 were stained for SMMHC, CD68, & nuclei (DAPI). n = 3. Boxed regions (a, c) are shown as close-ups on right; in c CD68+SMMHC+ cells in the media (arrowheads) & plaque (arrows) of the Itgb3 null atherosclerotic aorta are indicated. Med, tunica media; Lu, lumen; Pl, plaque. Scale bars, 25 μm. d–h Aortic SMCs were isolated from ApoE(−/−) mice & then subjected to siRNA-mediated knockdown with si-Itgb3 vs. scrambled (Scr; d–f) or with si-Itgb3, si-Tlr4 vs. si-Itgb3 (g, h). Levels of indicated transcripts from qRT-PCR are relative to Gapdh & normalized to either Scr in d, f or to si-Itgb3 in g, h. For d, g, n = 4–5 in duplicate. In e silenced SMCs were cultured with DiI-conjugated ox-LDL for 10 h & stained with DAPI; n = 5. In f, h silenced SMCs were exposed to soluble cholesterol:methyl-beta -cyclodextrin complexes for 3 days, & then mRNA levels were assessed; n = 4–7 in duplicate. *, **, ***, ^, **** vs. control (Scr in d, f & si-Itgb3 in g, h), p < 0.05, p < 0.01, p < 0.005, p < 0.001, & p < 0.0005, respectively. NS, not significant. Student’s t-test was used, & error bars represent standard deviations. i Schematic of the effect of beta 3 reduction via TLR4 & CD36 in SMCs on transdifferentiation Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-04447-7), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202416161810.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) & protein levels of VLDLR & NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) & protein levels of VLDLR (e) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36 (f), NQO1 (g) & PPAR gamma (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate & ML385 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32912335), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241616372.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) & protein levels of VLDLR & NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) & protein levels of VLDLR (e) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36 (f), NQO1 (g) & PPAR gamma (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate & ML385 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32912335), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241617350.jpg)
![Immunohistochemistry: CD36 Antibody [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), and DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 um. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) and TLR2 (green). Scale bar = 5 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-49472-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD36-Antibody-Immunohistochemistry-NB400-145-img0009.jpg "Immunohistochemistry: CD36 Antibody [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), and DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 um. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) and TLR2 (green). Scale bar = 5 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-49472-8), licensed under a CC-BY license.")
![Simple Western: CD36 Antibody [NB400-145] - Image shows a specific band for CD36 in human adipose lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD36-Antibody-Simple-Western-NB400-145-img0007.jpg)
![Western Blot: CD36 Antibody [NB400-145] - Detection of CD36 in human adipocyte extract (30 ug). Lane 1: 0.5 ug/ml NB 400-145; lane 2: 2 ug/ml NB 400-145. ECL: 3 second exposure.](http://images.novusbio.com/fullsize/CD36-Antibody-Western-Blot-NB400-145-img0006.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618930.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241616182.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618949.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-310202416173513.jpg)
![Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Western blot shows lysates of human placenta tissue and human platelets. PVDF membrane was probed with 1 ug/ml of Rabbit Anti-Human CD36 Monoclonal antibody (catalog number NBP2-54790) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (catalog number HAF008). A specific band was detected for CD36/SR-B3 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Western-Blot-NBP2-54790-img0023.jpg "Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Western blot shows lysates of human placenta tissue and human platelets. PVDF membrane was probed with 1 ug/ml of Rabbit Anti-Human CD36 Monoclonal antibody (catalog number NBP2-54790) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (catalog number HAF008). A specific band was detected for CD36/SR-B3 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions.")
![Immunohistochemistry-Paraffin: CD36 Antibody (1283D) [NBP2-54790] - CD36 was detected in immersion fixed paraffin-embedded sections of human heart using Rabbit Anti-Human CD36/SR-B3 Monoclonal Antibody for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte(TM) HRP Polymer Antibody. Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cardiomyocyte membranes.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Immunohistochemistry-Paraffin-NBP2-54790-img0002.jpg)
![Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Total protein from human skin and adipose tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-CD36 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Western-Blot-NBP2-54790-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD36 Antibody (1283D) [NBP2-54790] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-CD36 (1283D) at 5.0 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective..](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Immunocytochemistry-Immunofluorescence-NBP2-54790-img0003.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - 3T3-L1 adipocytes were pretreated and treated with ML348 (10 uM) for 1 h, followed by BSA or oleate treatment for another 1 h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD36-Antibody-1283D-BSA-Free-Western-Blot-NBP2-54790-img0024.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - LYN phosphorylates DHHC5 & is required for the endocytosis of FAs.a 3T3-L1 adipocytes pretreated with serum-free medium for 4 h & PP2 (15 μM) for 1 h, followed by treatment with BSA or oleate (100 μM) for 5 min. Cells harvested & immunoprecipitated with anti-DHHC5 antibody to detect phosphorylation of Tyr91. b 3T3-L1 adipocytes transduced with indicated shRNA set up & treated with oleate for 5 min. Cells harvested to detect Tyr91 phosphorylation as in (a). c On day 0, HEK293T cells set up at 2.5 × 105 cells per 6-cm dish. On day 2, cells transfected with 0.5 μg of WT, Y91E, or Y91F of DHHC5-Flag/pCDH-puro and/or 0.5 μg LYN/pCDNA3.3. On day 3, cells harvested & immunoprecipitated with anti-Flag M2 beads to detect phosphorylation of DHHC5 (pY). Control & LYN knockdown adipocytes pretreated & treated with BSA or oleate (100 μM) for 1 h, followed by immunostaining (d), surface biotinylation (e), & Acyl-RAC (f) assays. Control & CD36 knockdown 3T3-L1 adipocytes pretreated & treated with oleate (100 μM) for indicated time (g) or 5 min (h). Cells harvested & subjected to immunoprecipitation of LYN to detect phosphorylation of LYN (Y396). i, j WT & Cd36−/− SVFs set up & subjected to FA uptake as in Fig. 3h, i, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 20 cells. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. k WT & Cd36−/− adipocytes set up & subjected to 3H-oleate uptake as in Fig. 3j, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 3samples. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. These experiments repeated at least twice. Source data provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-3102024161365.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - LYN phosphorylates DHHC5 & is required for the endocytosis of FAs.a 3T3-L1 adipocytes pretreated with serum-free medium for 4 h & PP2 (15 μM) for 1 h, followed by treatment with BSA or oleate (100 μM) for 5 min. Cells harvested & immunoprecipitated with anti-DHHC5 antibody to detect phosphorylation of Tyr91. b 3T3-L1 adipocytes transduced with indicated shRNA set up & treated with oleate for 5 min. Cells harvested to detect Tyr91 phosphorylation as in (a). c On day 0, HEK293T cells set up at 2.5 × 105 cells per 6-cm dish. On day 2, cells transfected with 0.5 μg of WT, Y91E, or Y91F of DHHC5-Flag/pCDH-puro and/or 0.5 μg LYN/pCDNA3.3. On day 3, cells harvested & immunoprecipitated with anti-Flag M2 beads to detect phosphorylation of DHHC5 (pY). Control & LYN knockdown adipocytes pretreated & treated with BSA or oleate (100 μM) for 1 h, followed by immunostaining (d), surface biotinylation (e), & Acyl-RAC (f) assays. Control & CD36 knockdown 3T3-L1 adipocytes pretreated & treated with oleate (100 μM) for indicated time (g) or 5 min (h). Cells harvested & subjected to immunoprecipitation of LYN to detect phosphorylation of LYN (Y396). i, j WT & Cd36−/− SVFs set up & subjected to FA uptake as in Fig. 3h, i, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 20 cells. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. k WT & Cd36−/− adipocytes set up & subjected to 3H-oleate uptake as in Fig. 3j, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 3samples. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. These experiments repeated at least twice. Source data provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114783.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416121990.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-31020241612242.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114740.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114741.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - CD36-mediated caveolar endocytosis transports FAs into cells.a–c 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated PacFA (50 μM) for 20 min, followed by UV crosslinking on ice for 30 min. a, b Cells were subjected to click chemistry using an N3-Alexa Fluro 488, & immunostained with anti-CD36 antibody. Colocalization of PacFA & CD36 was quantified from 24 cells over three independent experiments & plotted in (b). The value represents mean ± SEM. c Cells were lysed & subjected to click chemistry assay using N3-biotin. PacFA-labeled proteins were captured with streptavidin beads & subjected to western blot using anti-CD36 & anti-FABP4 antibodies. d WT, Cav1−/−, Cd36−/−, & Cav1−/−;Cd36−/− SVFs were isolated & differentiated into adipocytes & treated with 100 μM 3H-oleate (specific activity, 2268 dpm/nmol) for 1 h. Lipid fractions were extracted from the cells & subjected to scintillation counting. The radioactive counting was normalized to protein content. Each value represents mean ± SEM obtained from three samples. Two-sided Student’s t test was performed between WT & each of the knockout cells. These experiments were repeated twice. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416113520.jpg)
![Western Blot: CD36 Antibody (D-2712) [NB110-59724] - Detection of CD36 in mouse adipose lysate.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-D-2712-Western-Blot-NB110-59724-img0007.jpg "Western Blot: CD36 Antibody (D-2712) [NB110-59724] - Detection of CD36 in mouse adipose lysate.")
![Immunohistochemistry: CD36 Antibody (D-2712) [NB110-59724] - Staining of CD36 in mouse liver.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-D-2712-Immunohistochemistry-NB110-59724-img0006.jpg)
![Immunohistochemistry-Paraffin: CD36 Antibody (FA6-152) [NB600-1423] - CD36, Human](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-FA6-152-Immunohistochemistry-Paraffin-NB600-1423-img0003.jpg "Immunohistochemistry-Paraffin: CD36 Antibody (FA6-152) [NB600-1423] - CD36, Human")
![Flow Cytometry: CD36 Antibody (FA6-152) [NB600-1423] - CD36, Human](http://images.novusbio.com/fullsize/CD36-Antibody-FA6-152-Flow-Cytometry-NB600-1423-img0007.jpg)
![Immunohistochemistry-Frozen: CD36 Antibody (FA6-152) [NB600-1423] - Frozen section of tonsil tissue. Staining especially in vascular endothelia.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-FA6-152-Immunohistochemistry-Frozen-NB600-1423-img0001.jpg)
![Western Blot: CD36 Antibody (877302) [MAB19553] - Analysis of human platelets tissue lysate with 1 ug/ml of hCD36 Monoclonal Antibody followed by HRP-conjugated Anti-Rabbit IgG Antibody. A specific band was detected for hCD36 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-877302-Western-Blot-MAB19553-img0002.jpg "Western Blot: CD36 Antibody (877302) [MAB19553] - Analysis of human platelets tissue lysate with 1 ug/ml of hCD36 Monoclonal Antibody followed by HRP-conjugated Anti-Rabbit IgG Antibody. A specific band was detected for hCD36 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.")
![Immunocytochemistry: CD36 Antibody (877302) [MAB19553] - CD36 was detected in immersion fixed U937 cell using CD36 Monoclonal Antibody at 8 ug/ml dilution. Cells were stained using the NorthernLights 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cytoplasmic.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-877302-Immunocytochemistry-MAB19553-img0001.jpg)
![Immunohistochemistry: CD36 Antibody (877302) [MAB19553] - CD36 was detected in immersion fixed paraffin-embedded sections of human heart using CD36 Monoclonal Antibody at 5 ug/ml. Tissue was stained using Mouse IgG VisUCyte HRP Polymer Antibody (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane in cardiomyocytes.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-877302-Immunohistochemistry-MAB19553-img0003.jpg)
